Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Cash & Equivalents: 2019-2024

Historic Cash & Equivalents for Avidity Biosciences (RNA) over the last 6 years, with Dec 2024 value amounting to $219.9 million.

  • Avidity Biosciences' Cash & Equivalents fell 5.40% to $350.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $350.2 million, marking a year-over-year decrease of 5.40%. This contributed to the annual value of $219.9 million for FY2024, which is 18.79% up from last year.
  • According to the latest figures from FY2024, Avidity Biosciences' Cash & Equivalents is $219.9 million, which was up 18.79% from $185.1 million recorded in FY2023.
  • In the past 5 years, Avidity Biosciences' Cash & Equivalents registered a high of $340.4 million during FY2022, and its lowest value of $185.1 million during FY2023.
  • Over the past 3 years, Avidity Biosciences' median Cash & Equivalents value was $219.9 million (recorded in 2024), while the average stood at $248.4 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first spiked by 239.89% in 2020, then slumped by 45.63% in 2023.
  • Yearly analysis of 5 years shows Avidity Biosciences' Cash & Equivalents stood at $321.5 million in 2020, then dropped by 0.32% to $320.4 million in 2021, then grew by 6.23% to $340.4 million in 2022, then plummeted by 45.63% to $185.1 million in 2023, then increased by 18.79% to $219.9 million in 2024.